Insomnia Therapeutics Market Size, Share & Trends Report

Insomnia Therapeutics Market Size, Share & Trends Analysis Report By Type (Benzodiazepines, Nonbenzodiazepines, Antidepressants), By Sales Channel (Prescription, OTC), By Region, And Segment Forecasts, 2024 - 2030

Report ID: GVR-2-68038-213-6
Number of Report Pages: 120
Format: PDF, Horizon Databook

Historical Range: 2018 - 2022
Forecast Period: 2024 - 2030
Industry: Healthcare

Table of Contents

Chapter 1. Methodology and Scope
  1.1. Market Segmentation and Scope
  1.2. Market Definitions
  1.3. Research Methodology
  1.3.1. Information Procurement
  1.3.2. Information or Data Analysis
  1.3.3. Market Formulation & Data Visualization
  1.3.4. Data Validation & Publishing
  1.4. Research Scope and Assumptions
  1.4.1. List of Data Sources
Chapter 2. Executive Summary
  2.1. Market Outlook
  2.2. Segment Outlook
  2.3. Competitive Insights
Chapter 3. Insomnia Therapeutics Variables, Trends, & Scope
  3.1. Market Introduction/Lineage Outlook
  3.2. Market Size and Growth Prospects (USD Million)
  3.3. Market Dynamics
  3.3.1. Market Drivers Analysis
  3.3.2. Market Restraints Analysis
  3.4. Insomnia Therapeutics Analysis Tools
  3.4.1. Porter’s Analysis
  3.4.1.1. Bargaining power of the suppliers
  3.4.1.2. Bargaining power of the buyers
  3.4.1.3. Threats of substitution
  3.4.1.4. Threats from new entrants
  3.4.1.5. Competitive rivalry
  3.4.2. PESTEL Analysis
  3.4.2.1. Political landscape
  3.4.2.2. Economic and Social landscape
  3.4.2.3. Technological landscape
  3.4.2.4. Environmental landscape
  3.4.2.5. Legal landscape
Chapter 4. Insomnia Therapeutics Market: Type Estimates & Trend Analysis
  4.1. Segment Dashboard
  4.2. Insomnia Therapeutics Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  4.3. Benzodiazepines
  4.3.1. Benzodiazepines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  4.4. Nonbenzodiazepines
  4.4.1. Nonbenzodiazepines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  4.5. Antidepressants
  4.5.1. Antidepressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  4.6. Orexin Antagonists
  4.6.1. Orexin Antagonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  4.7. Melatonin Antagonists
  4.7.1. Melatonin Antagonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  4.8. Others
  4.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Insomnia Therapeutics Market: Sales Channel Estimates & Trend Analysis
  5.1. Segment Dashboard
  5.2. Insomnia Therapeutics Market: Sales Channel Movement Analysis, 2023 & 2030 (USD Million)
  5.3. Prescription
  5.3.1. Prescription Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.4. Over-the Counter
  5.4.1. Over-the Counter Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Insomnia Therapeutics Market: Regional Estimates & Trend Analysis
  6.1. Insomnia Therapeutics Share, By Region, 2023 & 2030 (USD Million)
  6.2. North America
  6.2.1. North America Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.2.2. U.S.
  6.2.2.1. U.S. Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.2.3. Canada
  6.2.3.1. Canada Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.2.4. Mexico
  6.2.4.1. Mexico Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.3. Europe
  6.3.1. Europe Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.3.2. U.K.
  6.3.2.1. U.K. Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.3.3. Germany
  6.3.3.1. Germany Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.3.4. France
  6.3.4.1. France Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.3.5. Italy
  6.3.5.1. Italy Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.3.6. Spain
  6.3.6.1. Spain Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.3.7. Denmark
  6.3.7.1. Denmark Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.3.8. Sweden
  6.3.8.1. Sweden Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.3.9. Norway
  6.3.9.1. Sweden Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.4. Asia Pacific
  6.4.1. Asia Pacific Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.4.2. Japan
  6.4.2.1. Japan Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.4.3. China
  6.4.3.1. China Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.4.4. India
  6.4.4.1. India Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.4.5. South Korea
  6.4.5.1. South Korea Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.4.6. Thailand
  6.4.6.1. Thailand Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.5. Latin America
  6.5.1. Latin America Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.5.2. Brazil
  6.5.2.1. Brazil Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.5.3. Argentina
  6.5.3.1. Argentina Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.6. Middle East and Africa
  6.6.1. Middle East and Africa Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.6.2. South Africa
  6.6.2.1. South Africa Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.6.3. Saudi Arabia
  6.6.3.1. Saudi Arabia Insomnia Therapeutics and Forecasts, 2018 - 2030 (USD Million)
  6.6.4. UAE
  6.6.4.1. Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.6.5. Kuwait
  6.6.5.1. Kuwait Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
  7.1. Recent Developments & Impact Analysis by Key Market Participants
  7.2. Company Categorization
  7.3. Company Heat Map Analysis
  7.4. Company Profiles
  7.4.1. Takeda Pharmaceutical Company Ltd.
  7.4.1.1. Participant’s Overview
  7.4.1.2. Financial Performance
  7.4.1.3. Product Benchmarking
  7.4.1.4. Recent Developments/ Strategic Initiatives
  7.4.2. Vanda Pharmaceuticals
  7.4.2.1. Participant’s Overview
  7.4.2.2. Financial Performance
  7.4.2.3. Product Benchmarking
  7.4.2.4. Recent Developments/ Strategic Initiatives
  7.4.3. Merck & Co., Inc.
  7.4.3.1. Participant’s Overview
  7.4.3.2. Financial Performance
  7.4.3.3. Product Benchmarking
  7.4.3.4. Recent Developments/ Strategic Initiatives
  7.4.4. Pfizer Inc.
  7.4.4.1. Participant’s Overview
  7.4.4.2. Financial Performance
  7.4.4.3. Product Benchmarking
  7.4.4.4. Recent Developments/ Strategic Initiatives
  7.4.5. Teva Pharmaceutical Industries Ltd.
  7.4.5.1. Participant’s Overview
  7.4.5.2. Financial Performance
  7.4.5.3. Product Benchmarking
  7.4.5.4. Recent Developments/ Strategic Initiatives
  7.4.6. Mylan N.V.
  7.4.6.1. Participant’s Overview
  7.4.6.2. Financial Performance
  7.4.6.3. Product Benchmarking
  7.4.6.4. Recent Developments/ Strategic Initiatives
  7.4.7. Sumitomo Dainippon Pharma Co., Ltd
  7.4.7.1. Participant’s Overview
  7.4.7.2. Financial Performance
  7.4.7.3. Product Benchmarking
  7.4.7.4. Recent Developments/ Strategic Initiatives
  7.4.8. Sanofi
  7.4.8.1. Participant’s Overview
  7.4.8.2. Financial Performance
  7.4.8.3. Product Benchmarking
  7.4.8.4. Recent Developments/ Strategic Initiatives
  7.4.9. Paratek Pharmaceuticals Inc.
  7.4.9.1. Participant’s Overview
  7.4.9.2. Financial Performance
  7.4.9.3. Product Benchmarking
  7.4.9.4. Recent Developments/ Strategic Initiatives
  7.4.10. Ebb Therapeutics
  7.4.10.1. Participant’s Overview
  7.4.10.2. Financial Performance
  7.4.10.3. Product Benchmarking
  7.4.10.4. Recent Developments/ Strategic Initiatives

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.